Literature DB >> 457861

Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.

C H Packman, S I Rosenfeld, D E Jenkins, P A Thiem, J P Leddy.   

Abstract

Although enhanced sensitivity of erythrocytes to complement-mediated lysis is a hallmark of paroxysmal nocturnal hemoglobinuria (PNH), subpopulations of erythrocytes in such patients vary significantly in this respect. One PNH erythrocyte subpopulation (termed type III) comprises exquisitely sensitive cells, whereas type II PNH erythrocytes are intermediate in complement sensitivity between PNH type III and normal human erythrocytes. Differences in the action of the terminal complement components that would account for the differing lytic behavior of types II and III PNH erythrocytes have been proposed but not directly demonstrated. The present studies, making use of carefully selected cases with pure populations of type II or type III erythrocytes, confirm a prior observation that antibody-coated PNH erythrocytes of both types II and III display comparably supranormal C3 binding in whole human serum. However, when lysis was induced by the isolated C5b-9 membrane attack mechanism, bypassing the requirement for C3 binding, only type III PNH cells exhibited greater than normal lysis. This finding suggests that type III PNH erythrocytes have an additional membrane abnormality not present in type II cells. Thus, the differing lytic behavior of these two cell types in whole serum may reflect the additive effects on type III cells of both exaggerated C3 binding and enhanced sensitivity to C5b-9, whereas the more moderate lysis of type II PNH cells may be determined mainly or entirely by the earlier-acting mechanism producing augmented C3 binding. The failure of guinea pig C8 and C9, as opposed to human C8 and C9, to reveal the true lytic sensitivity of PNH-III E in our earlier study is illustrated, and its implications briefly discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 457861      PMCID: PMC372136          DOI: 10.1172/JCI109479

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  Reaction mechanisms of nascent C567 (reactive lysis). I. Reaction characteristics for production of EC567 and lysis by C8 and C9.

Authors:  J N Goldman; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1972-08       Impact factor: 5.422

2.  Additional studies on human C5: development of a modified purification method and characterization of the purified product by polyacrylamide gel electrophoresis.

Authors:  U R Nilsson; R H Tomar; F B Taylor
Journal:  Immunochemistry       Date:  1972-07

3.  Radioactive antiglobulin testing with 125I anti-C4 and anti-C3.

Authors:  D E Jenkins; R M Johnson; W H Moore
Journal:  Transfusion       Date:  1978 Jul-Aug       Impact factor: 3.157

4.  The C5b-6 complex: reaction with C7, C8, C9.

Authors:  E R Podack; G Biesecker; W P Kolb; H J Müller-Eberhard
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

5.  Differences in the terminal steps of complement lysis of normal and paroxysmal nocturnal hemoglobinuria red cells.

Authors:  T A Rouault; W F Rosse; S Bell; J Shelburne
Journal:  Blood       Date:  1978-02       Impact factor: 22.113

6.  The complex of C5b and C6: isolation, characterization, and identification of a modified form of C5b consisting of three polypeptide chains.

Authors:  K I Yamamoto; G Gewurz
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

7.  Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.

Authors:  T F Lint; C L Behrends; P J Baker; H Gewurz
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

8.  Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.

Authors:  G L Logue; W F Rosse; J P Adams
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

9.  Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.

Authors:  P J Lachmann; R A Thompson
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

10.  Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7.

Authors:  R A Thompson; P J Lachmann
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

View more
  22 in total

Review 1.  Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.

Authors:  C J Parker
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

Review 2.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 3.  [Paroxysmal nocturnal hemoglobinuria].

Authors:  P Blaas; S Weber; G M Hänsch; H H Peter
Journal:  Klin Wochenschr       Date:  1990-03-05

4.  Fc microparticles can modulate the physical extent and magnitude of complement activity.

Authors:  Brandon Alexander Holt; Michael C Bellavia; Daniel Potter; David White; Sean R Stowell; Todd Sulchek
Journal:  Biomater Sci       Date:  2017-02-28       Impact factor: 6.843

Review 5.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

6.  Abnormality of glycophorin-alpha on paroxysmal nocturnal hemoglobinuria erythrocytes.

Authors:  C J Parker; C M Soldato; W F Rosse
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

7.  Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.

Authors:  A Nicholson-Weller; J P March; S I Rosenfeld; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

8.  Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.

Authors:  P J Baker; C J Parker; S G Osofsky
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

9.  Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.

Authors:  G M Hänsch; S Schönermark; D Roelcke
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

10.  Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization.

Authors:  V W Hu; A Nicholson-Weller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.